Oaktree Acquisition Corp. III Reports Net Income of $1.66M for Quarter Ending March 31, 2025

Oaktree Acquisition Corp. III Life Sciences reported its financial results for the quarter ending March 31, 2025, revealing a net income of $1,658,791, primarily driven by interest income of $2,103,593 from cash held in its trust account. The company incurred general and administrative expenses totaling $444,802 during the same period. This marks a significant increase in net income compared to the previous fiscal period, where the company reported a net loss of $6,075,009, reflecting a shift towards profitability as it continues to prepare for its initial business combination.

As of March 31, 2025, Oaktree Acquisition Corp. III had total assets of $197,240,594, which includes $195,682,615 held in its trust account, up from $193,579,022 at the end of the previous fiscal year. The company’s current liabilities increased to $1,058,504 from $727,323, largely due to accrued expenses and a related party loan of $480,833. The total shareholders' deficit widened to $(6,519,273) from $(6,074,471), primarily due to the accretion of common stock to redemption amounts.

The company, which is classified as a non-accelerated filer and an emerging growth company, has not yet identified a specific target for its business combination. It completed its initial public offering on October 25, 2024, raising $175 million by selling 17,500,000 units at $10.00 each. Following the IPO, the company also sold 550,000 private placement units to its sponsor for $5.5 million. The funds raised are intended to be used for the business combination and related operational expenses.

Operationally, Oaktree Acquisition Corp. III has not commenced any business activities beyond its formation and the search for a target company. As of the end of the reporting period, the company had 19,783,010 Class A ordinary shares and 4,799,758 Class B ordinary shares outstanding. The company’s management has indicated that it expects to continue incurring significant costs in pursuit of its acquisition plans, and it may rely on loans from its sponsor or affiliates to cover operational expenses until a business combination is completed.

Looking ahead, Oaktree Acquisition Corp. III remains focused on identifying a suitable target for its business combination. The company has acknowledged the inherent risks associated with its operations, including market conditions and the potential for increased competition in the life sciences sector. The management team is committed to leveraging the funds in the trust account to facilitate a successful merger or acquisition, although there is no assurance that such a transaction will be completed within the anticipated timeframe.